“We currently see eight GLP-1s assets in the market. We’re covering six of those already, and we’re going to look to add as the market is evolving,” Sandoz has revealed, as it delved deeper into what it estimates is a near $60bn loss of exclusivity opportunity in the next decade.
Sandoz Is Covering ‘Six Of Eight’ GLP-1 Opportunities, With Plans To Evolve
Greater Free Cash Flow In Years Ahead Will Fuel Ambitions; API Supply Crucial
“I’ve never launched a drug quite like this,” Sandoz’s CEO Richard Saynor has admitted frankly, as the firm spoke about its plans to launch GLP-1 assets in the future, starting with semaglutide in markets including Canada and Brazil as early as 2026.
